These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32148541)

  • 1. Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology.
    Xu W; Tang M; Wang J; Wang L
    Evid Based Complement Alternat Med; 2020; 2020():4086864. PubMed ID: 32148541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ameliorative effect of CangFu Daotan Decoction on polycystic ovary syndrome of rodent model is associated with m6A methylation and Wnt/β-catenin pathway.
    Zhang Y; Zhou H; Ding C
    Gynecol Endocrinol; 2023 Dec; 39(1):2181637. PubMed ID: 36822223
    [No Abstract]   [Full Text] [Related]  

  • 3. A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome.
    Liu L; Du B; Zhang H; Guo X; Zhou Z; Xiu A; Liu C; Su S; Ai H
    Chin Med; 2018; 13():46. PubMed ID: 30181771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cangfu daotan decoction as an adjuvant treatment of Diane-35 for polycystic ovary syndrome: A systematic review and meta-analysis.
    Feng X; Cheng S; Xu S; Chen X; Zhou X
    Heliyon; 2024 Sep; 10(17):e36959. PubMed ID: 39281507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of
    Ma JX; Ye M; Ma K; Zhou K; Zhang Y; Wang X; Tong H
    Evid Based Complement Alternat Med; 2021; 2021():6651307. PubMed ID: 34457027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.
    Guan HR; Li B; Zhang ZH; Wu HS; He XL; Dong YJ; Su J; Lv GY; Chen SH
    BMC Complement Med Ther; 2023 Dec; 23(1):458. PubMed ID: 38102584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Cangfu Daotan Decoction on obese polycystic ovary syndrome and its mechanism.
    Yi W; Li X; Chen K; Zhu M; Cai X; Pan A
    Steroids; 2021 Jan; 165():108740. PubMed ID: 33137356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome.
    Fu Y; Xie P; Yang Q; Chen P; Yu J
    Prostaglandins Other Lipid Mediat; 2024 Feb; 170():106801. PubMed ID: 37984794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network pharmacology integrated with experimental validation reveals the regulatory mechanism of action of Hehuan Yin decoction in polycystic ovary syndrome with insulin resistance.
    Wu YY; Li SY; Zhu HQ; Zhuang ZM; Shao M; Chen FL; Liu CS; Tang QF
    J Ethnopharmacol; 2022 May; 289():115057. PubMed ID: 35121050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the molecular targets and mechanism of
    Yu H; Zhang L; Yin F; Zhan C; Chen J; Chu J
    Ann Transl Med; 2023 Feb; 11(3):149. PubMed ID: 36846000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on mechanism of Bushen Culuan Formula in treatment of polycystic ovary syndrome based on network pharmacology and molecular docking].
    Ma K; Gong LJ; Chen YX; Tian CD
    Zhongguo Zhong Yao Za Zhi; 2021 Jun; 46(11):2650-2659. PubMed ID: 34296561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified Cangfu Daotan decoction ameliorates polycystic ovary syndrome with insulin resistance
    Liu S; Zhang Y; Yang F; Gu J; Zhang R; Kuang Y; Mai W; Zheng C; Yu Y; Lu R; Zeng L; Cao H; Long Y
    Front Endocrinol (Lausanne); 2022; 13():975724. PubMed ID: 36440213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated Network Pharmacology and Clinical Study to Reveal the Effects and Mechanisms of Bushen Huoxue Huatan Decoction on Polycystic Ovary Syndrome.
    Ding J; Shanshan M; Mengcheng C; Danying Z; Jin Y
    Evid Based Complement Alternat Med; 2022; 2022():2635375. PubMed ID: 35600955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Zhen Wu Decoction in the Treatment of Heart Failure Based on Network Pharmacology and Molecular Docking.
    Ma CY; Ma YQ; Deng M
    Evid Based Complement Alternat Med; 2022; 2022():4877920. PubMed ID: 35341142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanism of Danggui Sini Decoction in treatment of primary dysmenorrhea based on network pharmacology and molecular docking].
    Que DH; Chen WH; Jiang FP; Pan F; Yang K
    Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(4):855-864. PubMed ID: 33645090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network pharmacology evaluation of the active ingredients and potential targets of XiaoLuoWan for application to uterine fibroids.
    Yu Y; Yang F; Liu H
    Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33196098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism and experimental verification of Dachengqi Decoction in treatment of sepsis based on network pharmacology].
    Fu ZH; Zhao LL; Zhou L; Li XC; Zhang XC
    Zhongguo Zhong Yao Za Zhi; 2021 Oct; 46(20):5351-5361. PubMed ID: 34738439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of Mahuang Lianqiao Chixiaodou Decoction in treating eczema by network pharmacology and molecular docking technology].
    Zhang XW; Liu AM; Zhao JJ; Guo J; Chen XY; Qu XX
    Zhongguo Zhong Yao Za Zhi; 2021 Feb; 46(4):894-901. PubMed ID: 33645094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Identification of potential targets and synergistic mechanism of Kushen Decoction for the treatment of cryptosporidiosis].
    Zhan N; Liu XH; Tang FY; Zhang JY
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2021 Oct; 33(5):483-495. PubMed ID: 34791846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
    Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
    J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.